Satavaptan (BioDeep_00000183165)

   

human metabolite blood metabolite


代谢物信息卡片


1-(4-(N-Tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro(4-(2-morpholinoethoxy)cyclohexane)indoline-2-one, phosphate monohydrate cis-isomer

化学式: C33H45N3O8S (643.292721)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCOC1=CC2=C(C=C1)N(C(=O)C21CCC(CC1)OCCN1CCOCC1)S(=O)(=O)C1=C(OC)C=C(C=C1)C(=O)NC(C)(C)C
InChI: InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)

描述信息

C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist
D045283 - Natriuretic Agents > D065092 - Antidiuretic Hormone Receptor Antagonists
D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents

同义名列表

7 个代谢物同义名

1-(4-(N-Tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro(4-(2-morpholinoethoxy)cyclohexane)indoline-2-one, phosphate monohydrate cis-isomer; N-Tert-butyl-4-({5-ethoxy-4-[2-(morpholin-4-yl)ethoxy]-2-oxo-1,2-dihydrospiro[cyclohexane-1,3-indole]-1-yl}sulphonyl)-3-methoxybenzene-1-carboximidic acid; N-Tert-butyl-4-({5-ethoxy-4-[2-(morpholin-4-yl)ethoxy]-2-oxo-1,2-dihydrospiro[cyclohexane-1,3-indole]-1-yl}sulphonyl)-3-methoxybenzene-1-carboximidate; N-Tert-butyl-4-({5-ethoxy-4-[2-(morpholin-4-yl)ethoxy]-2-oxo-1,2-dihydrospiro[cyclohexane-1,3-indole]-1-yl}sulfonyl)-3-methoxybenzene-1-carboximidate; N-tert-butyl-4-({5-ethoxy-4-[2-(morpholin-4-yl)ethoxy]-2-oxo-1,2-dihydrospiro[cyclohexane-1,3-indole]-1-yl}sulfonyl)-3-methoxybenzamide; 1-(4-(N-Tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro-(4-(2-morpholinoethoxy)cyclohexane)indol-2-one fumarate; Satavaptan



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Beril Erdem Tuncdemir, Hatice Mergen, Emel Saglar Ozer. Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins. European journal of pharmacology. 2019 Dec; 865(?):172803. doi: 10.1016/j.ejphar.2019.172803. [PMID: 31738937]
  • Hugh Watson, Monica Guevara, Hendrik Vilstrup, Pere Ginès. Improvement of hyponatremia in cirrhosis is associated with improved complex information processing. Journal of gastroenterology and hepatology. 2019 Nov; 34(11):1999-2003. doi: 10.1111/jgh.14683. [PMID: 30965392]
  • Clémence Cheignon, Emmanuelle Cordeau, Nolween Prache, Sonia Cantel, Jean Martinez, Gilles Subra, Carine Arnaudguilhem, Brice Bouyssiere, Christine Enjalbal. Receptor-Ligand Interaction Measured by Inductively Coupled Plasma Mass Spectrometry and Selenium Labeling. Journal of medicinal chemistry. 2018 11; 61(22):10173-10184. doi: 10.1021/acs.jmedchem.8b01320. [PMID: 30395477]
  • Florence Wong, Peter Jepsen, Hugh Watson, Hendrik Vilstrup. Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. Liver international : official journal of the International Association for the Study of the Liver. 2018 10; 38(10):1785-1792. doi: 10.1111/liv.13738. [PMID: 29532591]
  • Ray El Boustany, Christopher Taveau, Catherine Chollet, Gilberto Velho, Lise Bankir, François Alhenc-Gelas, Ronan Roussel, Nadine Bouby. Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes. Journal of diabetes and its complications. 2017 Jun; 31(6):929-932. doi: 10.1016/j.jdiacomp.2017.04.005. [PMID: 28412033]
  • Sunil Bhandari, Alessandro Peri, Iain Cranston, Rachael McCool, Alison Shaw, Julie Glanville, Larisa Petrakova, Karl O'Reilly. A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans. Clinical endocrinology. 2017 Jun; 86(6):761-771. doi: 10.1111/cen.13315. [PMID: 28214374]
  • Lars Bossen, Aleksander Krag, Hendrik Vilstrup, Hugh Watson, Peter Jepsen. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology (Baltimore, Md.). 2016 06; 63(6):1968-76. doi: 10.1002/hep.28352. [PMID: 26599983]
  • Jason D Hoffert, Trairak Pisitkun, Fahad Saeed, Justin L Wilson, Mark A Knepper. Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct. American journal of physiology. Renal physiology. 2014 Feb; 306(4):410-21. doi: 10.1152/ajprenal.00497.2013. [PMID: 24259510]
  • Yasukatsu Izumi, Katsuyuki Miura, Hiroshi Iwao. Therapeutic potential of vasopressin-receptor antagonists in heart failure. Journal of pharmacological sciences. 2014; 124(1):1-6. doi: 10.1254/jphs.13r13cp. [PMID: 24401675]
  • Nina Himmerkus, Birte Sievers, Markus Bleich. Carbamazepine affects water and electrolyte homoeostasis in rat--similarities and differences to vasopressin antagonism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012 Oct; 27(10):3790-8. doi: 10.1093/ndt/gfs107. [PMID: 22561584]
  • E Dahl, L L Gluud, N Kimer, A Krag. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Alimentary pharmacology & therapeutics. 2012 Oct; 36(7):619-26. doi: 10.1111/apt.12025. [PMID: 22908905]
  • Alain Soupart, Michel Coffernils, Bruno Couturier, Fabrice Gankam-Kengne, Guy Decaux. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clinical journal of the American Society of Nephrology : CJASN. 2012 May; 7(5):742-7. doi: 10.2215/cjn.06990711. [PMID: 22403276]
  • Stathis Hadjidemetriou, Wilfried Reichardt, Juergen Hennig, Martin Buechert, Dominik von Elverfeldt. Volumetric analysis of MRI data monitoring the treatment of polycystic kidney disease in a mouse model. Magma (New York, N.Y.). 2011 Apr; 24(2):109-19. doi: 10.1007/s10334-010-0240-9. [PMID: 21213015]
  • Doron Aronson, Joseph G Verbalis, Matthias Mueller, Henry Krum. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. European journal of heart failure. 2011 Mar; 13(3):327-36. doi: 10.1093/eurjhf/hfq226. [PMID: 21199833]
  • Benaya Rozen-Zvi, Dafna Yahav, Mihai Gheorghiade, Asher Korzets, Leonard Leibovici, Uzi Gafter. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2010 Aug; 56(2):325-37. doi: 10.1053/j.ajkd.2010.01.013. [PMID: 20538391]
  • Florence Wong, Pere Gines, Hugh Watson, Yves Horsmans, Paolo Angeli, Paul Gow, Pascal Minini, Mauro Bernardi. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. Journal of hepatology. 2010 Aug; 53(2):283-90. doi: 10.1016/j.jhep.2010.02.036. [PMID: 20541828]
  • Carles Villabona. [Vasopressin receptor antagonists: the vaptans]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion. 2010 May; 57 Suppl 2(?):41-52. doi: 10.1016/s1575-0922(10)70021-8. [PMID: 21130961]
  • P Ginès, F Wong, H Watson, R Terg, R Bruha, J-P Zarski, F Dudley. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. Alimentary pharmacology & therapeutics. 2010 Apr; 31(8):834-45. doi: 10.1111/j.1365-2036.2010.04236.x. [PMID: 20102356]
  • Detlef Bockenhauer, Eric Carpentier, Driss Rochdi, W van't Hoff, Billy Breton, Virginie Bernier, Michel Bouvier, Daniel G Bichet. Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus. Nephron. Physiology. 2010; 114(1):p1-10. doi: 10.1159/000245059. [PMID: 19816050]
  • Michelle Boone, Marleen Kortenoeven, Joris H Robben, Peter M T Deen. Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2010 Jan; 25(1):48-54. doi: 10.1093/ndt/gfp409. [PMID: 19666909]
  • Markus Haass. [Vasopressin receptor antagonists and heart failure]. Therapeutische Umschau. Revue therapeutique. 2009 Nov; 66(11):735-40. doi: 10.1024/0040-5930.66.11.735. [PMID: 19885790]
  • Sayali A Ranadive, Baran Ersoy, Helene Favre, Clement C Cheung, Stephen M Rosenthal, Walter L Miller, Christian Vaisse. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clinical endocrinology. 2009 Sep; 71(3):388-93. doi: 10.1111/j.1365-2265.2008.03513.x. [PMID: 19170711]
  • Stathis Hadjidemetriou, Wilfried Reichardt, Martin Buechert, Juergen Hennig, Dominik von Elverfeldt. Analysis of MR images of mice in preclinical treatment monitoring of polycystic kidney disease. Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention. 2009; 12(Pt 2):665-72. doi: 10.1007/978-3-642-04271-3_81. [PMID: 20426169]
  • Daniel Romaker, Michael Puetz, Sven Teschner, Johannes Donauer, Marcel Geyer, Peter Gerke, Brigitta Rumberger, Bernd Dworniczak, Petra Pennekamp, Björn Buchholz, H P H Neumann, Rajiv Kumar, Joachim Gloy, Kai-Uwe Eckardt, Gerd Walz. Increased expression of secreted frizzled-related protein 4 in polycystic kidneys. Journal of the American Society of Nephrology : JASN. 2009 Jan; 20(1):48-56. doi: 10.1681/asn.2008040345. [PMID: 18945944]
  • Frederic Chagnon, Vishal S Vaidya, Gerard E Plante, Joseph V Bonventre, Alfred Bernard, Chantal Guindi, Olivier Lesur. Modulation of aquaporin-2/vasopressin2 receptor kidney expression and tubular injury after endotoxin (lipopolysaccharide) challenge. Critical care medicine. 2008 Nov; 36(11):3054-61. doi: 10.1097/ccm.0b013e318186a938. [PMID: 18824919]
  • Julie Perucca, Daniel G Bichet, Pascale Bardoux, Nadine Bouby, Lise Bankir. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. Journal of the American Society of Nephrology : JASN. 2008 Sep; 19(9):1721-31. doi: 10.1681/asn.2008010021. [PMID: 18596120]
  • Pere Ginès, Mónica Guevara. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology (Baltimore, Md.). 2008 Sep; 48(3):1002-10. doi: 10.1002/hep.22418. [PMID: 18671303]
  • Bishara Bishara, Hiba Shiekh, Tony Karram, Irit Rubinstein, Zaher S Azzam, Niroz Abu-Saleh, Samy Nitecki, Joseph Winaver, Aaron Hoffman, Zaid A Abassi. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure. The Journal of pharmacology and experimental therapeutics. 2008 Aug; 326(2):414-22. doi: 10.1124/jpet.108.137745. [PMID: 18467593]
  • Ferenc Laczi. [Etiology, diagnostics and therapy of hyponatremias]. Orvosi hetilap. 2008 Jul; 149(29):1347-54. doi: 10.1556/oh.2008.28409. [PMID: 18617466]
  • Pere Ginès, Florence Wong, Hugh Watson, Slobodan Milutinovic, Luis Ruiz del Arbol, Dan Olteanu. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology (Baltimore, Md.). 2008 Jul; 48(1):204-13. doi: 10.1002/hep.22293. [PMID: 18508290]
  • Jalal K Ghali. Mechanisms, risks, and new treatment options for hyponatremia. Cardiology. 2008; 111(3):147-57. doi: 10.1159/000121596. [PMID: 18434717]
  • Ali K Ahrabi, Sara Terryn, Giovanna Valenti, Nathalie Caron, Claudine Serradeil-Le Gal, Danielle Raufaste, Soren Nielsen, Shigeo Horie, Jean-Marc Verbavatz, Olivier Devuyst. PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice. Journal of the American Society of Nephrology : JASN. 2007 Jun; 18(6):1740-53. doi: 10.1681/asn.2006010052. [PMID: 17475819]
  • Farhan Ali, Maya Guglin, Peter Vaitkevicius, Jalal K Ghali. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007; 67(6):847-58. doi: 10.2165/00003495-200767060-00002. [PMID: 17428103]
  • J H Robben, M Sze, N V A M Knoers, P M T Deen. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. American journal of physiology. Renal physiology. 2007 Jan; 292(1):F253-60. doi: 10.1152/ajprenal.00247.2006. [PMID: 16926443]
  • Alain Soupart, Peter Gross, Jean-Jacques Legros, Sándor Alföldi, Djillali Annane, Hassan M Heshmati, Guy Decaux. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clinical journal of the American Society of Nephrology : CJASN. 2006 Nov; 1(6):1154-60. doi: 10.2215/cjn.00160106. [PMID: 17699341]
  • Tsuyoshi Nishihashi, Cristina C Trandafir, Aimin Wang, Xu Ji, Kazuyoshi Kurahashi. Enhanced reactivity to vasopressin in rat basilar arteries during vasospasm after subarachnoid hemorrhage. European journal of pharmacology. 2005 Apr; 513(1-2):93-100. doi: 10.1016/j.ejphar.2005.01.051. [PMID: 15878713]
  • Lijun Yao, Dan-Yang Huang, Imke L Pfaff, Xin Nie, Michael Leitges, Volker Vallon. Evidence for a role of protein kinase C-alpha in urine concentration. American journal of physiology. Renal physiology. 2004 Aug; 287(2):F299-304. doi: 10.1152/ajprenal.00274.2003. [PMID: 15039142]
  • Pascale Bardoux, Patrick Bruneval, Didier Heudes, Nadine Bouby, Lise Bankir. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2003 Sep; 18(9):1755-63. doi: 10.1093/ndt/gfg277. [PMID: 12937221]
  • James Walter Ferguson, George Therapondos, David E Newby, Peter Clive Hayes. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clinical science (London, England : 1979). 2003 Jul; 105(1):1-8. doi: 10.1042/cs20030062. [PMID: 12639215]
  • Sonia Terrillon, Thierry Durroux, Bernard Mouillac, Andreas Breit, Mohammed A Ayoub, Magali Taulan, Ralf Jockers, Claude Barberis, Michel Bouvier. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Molecular endocrinology (Baltimore, Md.). 2003 Apr; 17(4):677-91. doi: 10.1210/me.2002-0222. [PMID: 12554793]
  • Claudine Serradeil-Le Gal, Jean Wagnon, Jacques Simiand, Guy Griebel, Colette Lacour, Gilles Guillon, Claude Barberis, Gabrielle Brossard, Philippe Soubrié, Dino Nisato, Marc Pascal, Rebecca Pruss, Bernard Scatton, Jean-Pierre Maffrand, Gérard Le Fur. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. The Journal of pharmacology and experimental therapeutics. 2002 Mar; 300(3):1122-30. doi: 10.1124/jpet.300.3.1122. [PMID: 11861823]
  • W Jiménez. [Aquaretic agents]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2002; 22 Suppl 5(?):52-5. doi: NULL. [PMID: 12107918]
  • Basit Javaid, Jean L Olson, Timothy W Meyer. Glomerular injury and tubular loss in adriamycin nephrosis. Journal of the American Society of Nephrology : JASN. 2001 Jul; 12(7):1391-1400. doi: 10.1681/asn.v1271391. [PMID: 11423568]
  • B Pouzet, C Serradeil-Le Gal, N Bouby, J P Maffrand, G Le Fur, L Bankir. Selective blockade of vasopressin V2 receptors reveals significant V2-mediated water reabsorption in Brattleboro rats with diabetes insipidus. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2001 Apr; 16(4):725-34. doi: 10.1093/ndt/16.4.725. [PMID: 11274265]
  • C Serradeil-Le Gal. An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist. Cardiovascular drug reviews. 2001; 19(3):201-14. doi: 10.1111/j.1527-3466.2001.tb00065.x. [PMID: 11607038]
  • C Serradeil-Le Gal, D Raufaste, E Double-Cazanave, G Guillon, C Garcia, M Pascal, J P Maffrand. Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney international. 2000 Oct; 58(4):1613-22. doi: 10.1046/j.1523-1755.2000.00322.x. [PMID: 11012895]
  • W Jiménez, C S Gal, J Ros, C Cano, P Cejudo, M Morales-Ruiz, V Arroyo, M Pascal, F Rivera, J P Maffrand, J Rodés. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats. The Journal of pharmacology and experimental therapeutics. 2000 Oct; 295(1):83-90. doi: NULL. [PMID: 10991964]
  • D Y Huang, I Pfaff, C Serradeil-Le Gal, V Vallon. Acute renal response to the non-peptide vasopressin V2-receptor antagonist SR 121463B in anesthetized rats. Naunyn-Schmiedeberg's archives of pharmacology. 2000 Sep; 362(3):201-7. doi: 10.1007/s002100000282. [PMID: 10997721]
  • M Saito, A Tahara, T Sugimoto, K Abe, K Furuichi. Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor. European journal of pharmacology. 2000 Aug; 401(3):289-96. doi: 10.1016/s0014-2999(00)00465-9. [PMID: 10936486]
  • D Promeneur, T H Kwon, J Frøkiaer, M A Knepper, S Nielsen. Vasopressin V(2)-receptor-dependent regulation of AQP2 expression in Brattleboro rats. American journal of physiology. Renal physiology. 2000 Aug; 279(2):F370-82. doi: 10.1152/ajprenal.2000.279.2.f370. [PMID: 10919858]
  • F Lacheretz, A Barbier, C Serradeil-Le Gal, P P Elena, J P Maffrand, G Le Fur. Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2000 Jun; 16(3):203-16. doi: 10.1089/jop.2000.16.203. [PMID: 10872918]
  • C Lacour, G Galindo, F Canals, D Segondy, C Cazaubon, C Serradeil-Le Gal, A Roccon, D Nisato. Aquaretic and hormonal effects of a vasopressin V(2) receptor antagonist after acute and long-term treatment in rats. European journal of pharmacology. 2000 Apr; 394(1):131-8. doi: 10.1016/s0014-2999(00)00088-1. [PMID: 10771045]
  • T Shen, J Laycock, Y Suzuki, N Defer, J Hanoune. Stability of the vasopressin V2 receptor-adenylyl cyclase system in rat kidney. European journal of pharmacology. 1998 Jan; 341(1):87-94. doi: 10.1016/s0014-2999(97)01461-1. [PMID: 9489860]
  • C Serradeil-Le Gal. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist. Advances in experimental medicine and biology. 1998; 449(?):427-38. doi: NULL. [PMID: 10026834]
  • C Kitiyakara, C S Wilcox. Vasopressin V2-receptor antagonists: panaceas for hyponatremia?. Current opinion in nephrology and hypertension. 1997 Sep; 6(5):461-7. doi: 10.1097/00041552-199709000-00009. [PMID: 9327205]
  • C Serradeil-Le Gal, C Lacour, G Valette, G Garcia, L Foulon, G Galindo, L Bankir, B Pouzet, G Guillon, C Barberis, D Chicot, S Jard, P Vilain, C Garcia, E Marty, D Raufaste, G Brossard, D Nisato, J P Maffrand, G Le Fur. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. The Journal of clinical investigation. 1996 Dec; 98(12):2729-38. doi: 10.1172/jci119098. [PMID: 8981918]